Современная терапия неходжкинских лимфом


Алексеева Ю.А.

Отделение химиотерапии онкогематологических заболеваний с блоком ТКМ ФЦСКЭ им В.А. Алмазова, Санкт-Петербург
Внедрение в последнее десятилетие химерного моноклонального антитела ритуксимаб в клиническую практику позволило добиться определенных успехов в лечении В-клеточных лимфом. Эффективность ритуксимаба показана как в монотерапии, так и в комбинации с химиотерапией, а также на этапе поддерживающего лечения. Дальнейшие успехи в лечении указанных заболеваний будут, вероятно, связаны с проведением риск-адаптированной терапии и комбинацией с таргетными генными ингибиторами.

Литература


1. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin lymphoma. N Engl J Med 1993;328(14);1002–06.
2. Hans CP, Weisenburger DD, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103(1): 275–82.
3. Rosenwald A, Wright G, Leroy K. Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma. J Experimen
Med 2003;198(6):851–62.
4. Gregory SA, Trumper L. Chemotherapy dose intensity in non-Hodgkins lymphoma: is dose intensity an emerging paradigm for better outcomes? Annals of Oncology 2005;16: 1413–24.
5. Barlett NL, Petroni GR. Dose-escalated CHOEP for patients with diffuse lymphoma. Cancer and Leukemia Group B studies 8852 and 8854. Cancer 2001;92:207–17.
6. Martelli N, Gherlinzoni F. Early autologous stemcell transplantation versus conventional chemotherapy as front-line therapy in high risk aggressive non-Hodgkins lymphoma; an Italian multicenter randomized trial. J Clin Oncol 2003;21:1255–62.
7. Vitolo U, Chiappella A, Angelucci E, et al. Dose-dense and high-dose chemotherapy plus Rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma at poor prognosis: a phase II multicenter study. Haematologica 2009;94(9):1250–58.
8. Pfreundschuh M. Therapy of diffuse large B-cell lymphomas. Eur J Cancer 45:386–87.
9. Cunningham D, Smith P, Mouncey P, et al. R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. J Clin Oncol 2011;29:abstract 8000.
10. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma. J Clin Oncol 2006;24(19):3121–27.
11. Giesselbrecht C, Schmitz N, Mounier N, et al. R-ICE versus R-DHAP in relapsed patients with CD20 difuse large B-cell lymphoma (DLBCL) followed by stem cell transplantation and maintenance treatment with rituximab or not: first interim analysis on 200 patients. CORAL study. Blood (ASH Annual Meeting Abstracts)
2007;110:517.
12. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558–65.
13. Determann O, Hoster E, Ott G, et al. Ki-67
predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the
German Low Grade Lymphoma Study Group.Blood 2008;111:2385–87.
14. Khouri IF, Romaguera J, Kantarjian H, et al. Champlin Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998;16(12):3803.
15. Ganti AK, Bierman PJ, Lynch JC, et al. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 2005;16:618–24.
16. Williams ME, Dreyling M, Winter J, et al. Management of Mantle Cell Lymphoma: Key Challenges and Next Steps. Clin Lymphoma Myeloma Leuk 2010;10(5):336–46.
17. Geisler CH, Kolstad A, Laurell A, et al. Longterm progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized Phase II multicenterstudy by the Nordic Lymphoma Group. Blood 2008;112:2687–93.
18. Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory
mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011;12(4):361.
19. Zhang L, Qian Z, Cai Z, et al. Synergistic antitumor effects of lenalidomide and rituximab on
mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009;84(9):553–59.
20. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011;22(7):1622.
21. Goy SH, Bernstein BS, Kahl B, et al. Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): Results of the PINNACLE study. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18S):7512.
22. Friedberg JW, Vose M, et al The combination of bendamustine, bortesomibe, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011;117:2807–12.
23. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156–64.
24. Gordan LN, Grow WB, Pusateri A, et al. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoprolif erative disorders. J Clin Oncol 2005;23:1096–102.
25. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009; 27:1607–14.
26. Moccia IA HP, Klasa R, Savage KJ, et al. Front-Line Therapy with Rituximab, Cyclophosphamide,
Vincristine, and Prednisone (R-CVP) Followed by 2 Years of Rituximab Maintenance for Follicular Lymphoma (FL) Is Associated with Excellent Outcomes and Improved Progression-Free Survival (PFS) In Comparison to No Maintenance. Blood (Meeting abstracts) 2010;116:1803.
27. Rummel MJ, Balser C, Stauch MB, et al. Bendamustine Plus Rituximab vs Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas –Final Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). Blood
(Meeting abstracts) 2010;116:856.
28. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009;145:344–49.
29. Rodriguez J, Conde E, Gutierrez A, et al. The results of consolidation with autologous stemcell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007;18:652–57.
30. Feyler S, Prince HM, Pearce R, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 2007;40:443–50.
31. Corradini P, Tarella C, Zallio F, et al. Longterm follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006;20:1533–38.
32. Minich SS. Brentuximab Vedotin: A New Age in the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma. Ann Pharmacother 2012;46:377–83.


Об авторах / Для корреспонденции


Алексеева Ю.А. – кандидат медицинских наук, заведующая отделением химиотерапии онкогематологических заболеваний с блоком ТКМ ФЦСКЭ им В.А. Алмазова


Похожие статьи


Бионика Медиа